Rare perianal extramammary Paget disease successfully treated using topical Imiquimod therapy

BMC Cancer. 2018 Sep 25;18(1):921. doi: 10.1186/s12885-018-4815-6.

Abstract

Background: Perianal Paget's disease (PPD) is a rare intraepithelial adenocarcinoma of the anal margin. Primary PPD likely represents intra-epithelial neoplasm from an apocrine source, whereas secondary disease may represent "pagetoid" spread from an anorectal malignancy.

Case presentation: Histologic CDX-2 and CK20 are hallmark markers for colorectal-derived Paget's cells. Interestingly, our primary PPD patient presented both positive and no internal malignancy was identified. In addition, a negative CK7 marker was observed in our case in contrast with previously reported. Surgical excision is the standard treatment; however, previous studies have demonstrated good response with Imiquimod 5% cream in patients with vulval extramammary Paget disease (EMPD). The efficiency of Imiquimod treatment for PPD has not been well described. Our PPD patient was successfully treated using Imiquimod 5% cream.

Conclusions: This study describes a primary cutaneous PPD patient CDX-2+/CK20+/CK7- without invasion of the dermis and no associated colorectal carcinoma effectively treated using topical Imiquimod therapy, suggesting that Imiquimod might potentially be considered as a first-line treatment for PPD.

Keywords: Differential diagnosis; Histological markers; Perianal Paget’s disease; Topical Imiquimod therapy.

Publication types

  • Case Reports

MeSH terms

  • Administration, Topical
  • Aged
  • Antineoplastic Agents / administration & dosage*
  • Anus Neoplasms / diagnosis*
  • Anus Neoplasms / drug therapy*
  • Biomarkers, Tumor
  • Biopsy
  • Humans
  • Imiquimod / administration & dosage*
  • Immunohistochemistry
  • Male
  • Paget Disease, Extramammary / diagnosis*
  • Paget Disease, Extramammary / drug therapy*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Imiquimod